AR071728A1 - Terapia con intervalos para el tratamiento del tinnitus - Google Patents

Terapia con intervalos para el tratamiento del tinnitus

Info

Publication number
AR071728A1
AR071728A1 ARP080103938A ARP080103938A AR071728A1 AR 071728 A1 AR071728 A1 AR 071728A1 AR P080103938 A ARP080103938 A AR P080103938A AR P080103938 A ARP080103938 A AR P080103938A AR 071728 A1 AR071728 A1 AR 071728A1
Authority
AR
Argentina
Prior art keywords
amino
tinnitus
dose
period
administered
Prior art date
Application number
ARP080103938A
Other languages
English (en)
Inventor
Tanja Rosenberg
Barbara Ellers-Lenz
Hagen Kruger
Michael Althaus
Hermann Russ
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR071728A1 publication Critical patent/AR071728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

Reivindicacion 1: Un derivado de 1-amino-alquilciclohexano para el tratamiento del tinnitus, caracterizado porque se administra una cantidad eficaz para el uso terapeutico del derivado de 1-amino-alquilciclohexano diariamente por un primer per¡odo de al menos tres (3) meses, a lo que sigue un segundo per¡odo de al menos un (1) mes, donde el derivado de 1-amino-alquilciclohexano se administra en una dosis que es 0-75% de la dosis con eficacia terapeutica. Reivindicacion 2: Uso de un derivado de 1-amino-alquilciclohexano caracterizado porque es para la fabricacion de un medicamento para tratar el tinnitus en un sujeto que lo necesita, donde se administra una cantidad eficaz para el uso terapeutico del derivado de 1-amino-alquilciclohexano diariamente por un primer per¡odo de al menos tres (3) meses, a lo que sigue un segundo per¡odo de al menos un (1) mes, donde el derivado de 1-amino-alquilciclohexano se administra en una dosis de 0-75% de la dosis con eficacia terapeutica.
ARP080103938A 2007-09-12 2008-09-10 Terapia con intervalos para el tratamiento del tinnitus AR071728A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US99339607P 2007-09-12 2007-09-12
EP07253630 2007-09-12
US6708308P 2008-02-25 2008-02-25
US6693108P 2008-02-25 2008-02-25
US6702608P 2008-02-25 2008-02-25
EP08004776 2008-03-14
EP08004778 2008-03-14
EP08004777 2008-03-14

Publications (1)

Publication Number Publication Date
AR071728A1 true AR071728A1 (es) 2010-07-14

Family

ID=40451596

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080103938A AR071728A1 (es) 2007-09-12 2008-09-10 Terapia con intervalos para el tratamiento del tinnitus
ARP080103936A AR070025A1 (es) 2007-09-12 2008-09-10 Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
ARP080103937A AR070026A1 (es) 2007-09-12 2008-09-10 Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP080103936A AR070025A1 (es) 2007-09-12 2008-09-10 Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
ARP080103937A AR070026A1 (es) 2007-09-12 2008-09-10 Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus

Country Status (21)

Country Link
US (6) US20110086916A1 (es)
EP (6) EP2200598A1 (es)
JP (6) JP5613053B2 (es)
KR (4) KR20100052556A (es)
CN (4) CN101801366A (es)
AR (3) AR071728A1 (es)
AT (1) ATE532507T1 (es)
AU (4) AU2008298017B2 (es)
BR (2) BRPI0816690A2 (es)
CA (4) CA2699209A1 (es)
DK (1) DK2200600T3 (es)
ES (5) ES2510565T3 (es)
HR (1) HRP20120046T1 (es)
MX (4) MX2010002733A (es)
PL (1) PL2200600T3 (es)
PT (1) PT2200600E (es)
RU (1) RU2011137131A (es)
SI (1) SI2200600T1 (es)
TW (3) TW200918042A (es)
WO (4) WO2009033650A1 (es)
ZA (4) ZA201001262B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2200600T3 (pl) * 2007-09-12 2012-04-30 Merz Pharma Gmbh & Co Kgaa Nerameksan do zastosowania w leczeniu podostrego szumu usznego
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2011160839A1 (en) 2010-06-24 2011-12-29 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
US20130296427A1 (en) * 2011-01-20 2013-11-07 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
CA2904055A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
CN106535883A (zh) * 2014-04-28 2017-03-22 杏林制药株式会社 耳鸣患者的治疗用药剂
EP3138559A4 (en) * 2014-04-28 2017-10-25 Kyorin Pharmaceutical Co., Ltd. Drug for treatment of tinnitus patients
CA2999467C (en) 2014-10-23 2023-10-10 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor
PL3297628T3 (pl) * 2015-05-18 2021-12-06 Sensorion Azasetron do stosowania w leczeniu niedosłuchu
KR101893604B1 (ko) 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
CN105924362B (zh) * 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
KR102268893B1 (ko) 2020-01-16 2021-06-24 경북대학교 산학협력단 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물
CN111477199B (zh) * 2020-04-02 2021-11-30 北京瑞迪欧文化传播有限责任公司 一种嵌入式音乐控制系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
CA2172509C (en) 1993-10-22 2010-08-24 Jeffrey L. Cleland Methods and compositions for microencapsulation of antigens for use as vaccines
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
AU4424697A (en) * 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
EP1009732B1 (en) * 1997-06-30 2003-05-21 MERZ + CO. GmbH & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
JP2003531187A (ja) * 2000-04-26 2003-10-21 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択的ｎｍｄａ受容体アンタゴニストとしてのシクロヘキシルアミン誘導体
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
JP2004021734A (ja) 2002-06-18 2004-01-22 Nokia Corp キーパッドおよびキーパッドシステム
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
EP1545551A4 (en) * 2002-09-06 2008-10-22 Durect Corp DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
EA010430B1 (ru) * 2003-05-27 2008-08-29 Форест Лэборэтериз, Инк. Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR20090033410A (ko) 2004-06-17 2009-04-02 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20060264897A1 (en) * 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2006096518A2 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Improved gacyclidine formulations
TWI265036B (en) * 2005-04-29 2006-11-01 Guo-Ming Huang Safety injector and method of operating the same
US8062205B2 (en) * 2005-05-18 2011-11-22 Gt Urological, Llc Drug elution for implantable incontinence devices
CN1896729A (zh) 2005-07-15 2007-01-17 复旦大学附属中山医院 纳米药物自组装双稳态量子线阵列及其制备方法
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
PL2200600T3 (pl) * 2007-09-12 2012-04-30 Merz Pharma Gmbh & Co Kgaa Nerameksan do zastosowania w leczeniu podostrego szumu usznego
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
AU2009291244A1 (en) * 2008-09-10 2010-03-18 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US20130296427A1 (en) * 2011-01-20 2013-11-07 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss

Also Published As

Publication number Publication date
CN101835469A (zh) 2010-09-15
CN101801366A (zh) 2010-08-11
JP5563461B2 (ja) 2014-07-30
US20110077304A1 (en) 2011-03-31
BRPI0816690A2 (pt) 2016-11-01
KR20100052559A (ko) 2010-05-19
CA2699209A1 (en) 2009-03-19
KR20100052557A (ko) 2010-05-19
CA2699207A1 (en) 2009-03-19
AU2008298017B2 (en) 2012-03-01
JP5784189B2 (ja) 2015-09-24
TW200922544A (en) 2009-06-01
CN101801365A (zh) 2010-08-11
TW200927087A (en) 2009-07-01
AU2008298017A1 (en) 2009-03-19
US20100298441A1 (en) 2010-11-25
US20170027885A1 (en) 2017-02-02
ES2596262T3 (es) 2017-01-05
US20110086916A1 (en) 2011-04-14
HRP20120046T1 (hr) 2012-02-29
EP2200599A1 (en) 2010-06-30
AU2008298016B2 (en) 2012-02-02
CN101795679A (zh) 2010-08-04
WO2009033650A1 (en) 2009-03-19
ZA201001262B (en) 2011-07-27
MX2010002735A (es) 2010-04-01
AU2008298016A1 (en) 2009-03-19
EP2200599B1 (en) 2016-08-31
AR070025A1 (es) 2010-03-10
EP2386299A2 (en) 2011-11-16
ES2377253T3 (es) 2012-03-23
BRPI0816712A2 (pt) 2016-11-08
EP2386299A3 (en) 2012-05-02
JP5613053B2 (ja) 2014-10-22
EP2203163A1 (en) 2010-07-07
AU2008298018A1 (en) 2009-03-19
KR20100052556A (ko) 2010-05-19
MX2010002736A (es) 2010-04-01
DK2200600T3 (da) 2012-01-23
JP2010539116A (ja) 2010-12-16
CA2699210A1 (en) 2009-03-19
AU2008298015B2 (en) 2012-03-22
EP2203163B1 (en) 2014-08-27
JP5563460B2 (ja) 2014-07-30
US20150018425A1 (en) 2015-01-15
ES2510565T3 (es) 2014-10-21
US20100298440A1 (en) 2010-11-25
MX2010002733A (es) 2010-04-09
MX2010002734A (es) 2010-04-01
EP2386299B1 (en) 2016-07-13
JP2010539115A (ja) 2010-12-16
PL2200600T3 (pl) 2012-04-30
AU2008298018B2 (en) 2012-01-19
EP2548552A3 (en) 2013-10-16
SI2200600T1 (sl) 2012-03-30
EP2200598A1 (en) 2010-06-30
JP5784188B2 (ja) 2015-09-24
WO2009033651A1 (en) 2009-03-19
EP2200600A1 (en) 2010-06-30
EP2200600B1 (en) 2011-11-09
KR20100052558A (ko) 2010-05-19
ZA201001263B (en) 2011-07-27
AR070026A1 (es) 2010-03-10
US8877814B2 (en) 2014-11-04
AU2008298015A1 (en) 2009-03-19
JP2014221767A (ja) 2014-11-27
TW200918042A (en) 2009-05-01
EP2548552B1 (en) 2015-11-18
ATE532507T1 (de) 2011-11-15
RU2011137131A (ru) 2013-03-20
JP5612473B2 (ja) 2014-10-22
AU2008298018C1 (en) 2012-08-16
ES2604945T3 (es) 2017-03-10
EP2548552A2 (en) 2013-01-23
PT2200600E (pt) 2012-02-17
JP2010539118A (ja) 2010-12-16
JP2014221766A (ja) 2014-11-27
ES2562709T3 (es) 2016-03-07
ZA201001261B (en) 2011-08-31
WO2009033649A1 (en) 2009-03-19
CA2699213A1 (en) 2009-03-19
US9468610B2 (en) 2016-10-18
JP2010539117A (ja) 2010-12-16
ZA201001264B (en) 2011-07-27
WO2009033652A1 (en) 2009-03-19
US9498450B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
AR071728A1 (es) Terapia con intervalos para el tratamiento del tinnitus
UY31205A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
CR11724A (es) Agente para tratar enfermedades
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
MX2009013989A (es) Terapia en combinacion para depresion.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
MX2009011444A (es) Titulacion del tapentadol.
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CL2009000009A1 (es) Kit biocida para aplicaciones agricolas que comprende una dosis de una solucion basica de hipoclorito y una dosis de una resina de intercambio cationico como agente regulador del ph, de manera que una vez mezcladas dichas dos dosis, el ph queda entre 5 y 8; metodo para tratamiento biocidas que comprende el uso de dicho kit.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
ES2422286T3 (es) Uso de apamina para tratar la enfermedad de Parkinson
CL2019003463A1 (es) Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas.
CL2009000322A1 (es) Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal